What is Nabriva Therapeutics AG's stock symbol?
Nabriva Therapeutics AG trades on the NASDAQ under the ticker symbol "NBRV."
Where is Nabriva Therapeutics AG's stock going? Where will Nabriva Therapeutics AG's stock price be in 2017?
5 brokers have issued 12-month price targets for Nabriva Therapeutics AG's shares. Their predictions range from $13.00 to $22.00. On average, they expect Nabriva Therapeutics AG's stock price to reach $15.80 in the next twelve months.
When will Nabriva Therapeutics AG announce their earnings?
Nabriva Therapeutics AG is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about Nabriva Therapeutics AG stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics AG stock:
According to Zacks Investment Research, "Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. " (2/4/2017)
- Wedbush analysts commented, "Nabriva recently reported that LEAP-1 has achieved 60% of its enrollment target, remaining on track to report data from both Ph 3 studies in 2H17 ' we believe both these readouts will be positive. In addition, we believe lefamulin's product profile possesses the key attributes required to take advantage of the commercial opportunity in CABP." (1/31/2017)
Who owns Nabriva Therapeutics AG stock?
Nabriva Therapeutics AG's stock is owned by many different of retail and institutional investors. Top institutional investors include Vivo Capital LLC (18.90%), Novo A S (10.93%), Orbimed Advisors LLC (7.89%), Acuta Capital Partners LLC (3.32%), Franklin Resources Inc. (1.64%) and EcoR1 Capital LLC (1.24%).
Who sold Nabriva Therapeutics AG stock? Who is selling Nabriva Therapeutics AG stock?
Nabriva Therapeutics AG's stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC.
Who bought Nabriva Therapeutics AG stock? Who is buying Nabriva Therapeutics AG stock?
Nabriva Therapeutics AG's stock was bought by a variety of institutional investors in the last quarter, including Novo A S, Vivo Capital LLC, Orbimed Advisors LLC, Acuta Capital Partners LLC, FT Options LLC and Renaissance Technologies LLC.
How do I buy Nabriva Therapeutics AG stock?
Shares of Nabriva Therapeutics AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nabriva Therapeutics AG stock cost?
One share of Nabriva Therapeutics AG stock can currently be purchased for approximately $10.78.